GLP-2 therapy (teduglutide) stimulates intestinal growth for short bowel syndrome, but rodent studies showing increased colon adenomas raise unresolved safety concerns about long-term cancer risk.
30 months — safety limitClinical data shows teduglutide is tolerated for up to 30 months, but rodent studies showing increased adenomas raise concerns about what happens with longer treatment
What the researchers found
GLP-2 stimulates intestinal growth through secondary mediators and Akt phosphorylation signaling, making it therapeutic for conditions like short bowel syndrome. However, rodent studies have shown that exogenous GLP-2 increases the growth and incidence of colon adenomas, raising concern that GLP-2 treatment could promote intestinal tumor development or progression.
Clinical studies show that exogenous GLP-2 treatment (as teduglutide) is well tolerated for up to 30 months, but the safety of longer treatment periods regarding intestinal cancer risk has not been established. The association between GLP-2 treatment and intestinal neoplasia in humans remains unclear.
Why it matters
Teduglutide (a GLP-2 analog) is an FDA-approved treatment for short bowel syndrome, a life-threatening condition where patients cannot absorb enough nutrition. The drug works by stimulating intestinal tissue growth — but this same growth-promoting property raises a critical safety question: could it also promote intestinal cancers? This review highlights a real clinical dilemma where a drug that provides essential benefit for one condition could theoretically increase risk of another. Patients on long-term teduglutide need monitoring, and the field needs better long-term safety data.
The numbers in context
Up to 30 months of tolerated clinical use · rodent data showing increased adenoma growth and incidence · Akt phosphorylation pathway · teduglutide (approved GLP-2 analog)
How the study worked
Narrative review based on PubMed literature searches using English keywords. The authors reviewed all published experimental (animal) and clinical (human) studies examining GLP-2's relationship to intestinal neoplasia. The review covers both the growth-stimulating mechanisms of GLP-2 and the available safety data from clinical use of teduglutide.
Who was studied
Review of animal and human studies on GLP-2 and intestinal tumor risk
What this study cannot tell us
The studies on GLP-2 and intestinal neoplasia are described as 'sparse,' limiting the strength of conclusions. The rodent tumor data may not directly translate to humans. Clinical safety data extends only to 30 months. As a narrative rather than systematic review, study selection may not be comprehensive. The review cannot establish causation between GLP-2 treatment and cancer risk in humans.
How to read the evidence
This is rated Moderate because it reviews both experimental animal data and clinical human safety data from a well-characterized therapeutic, but the key cancer concern is based primarily on rodent studies with limited human evidence. The sparse literature on this topic limits the strength of conclusions.
When this study was published
Published in 2018, this review captured safety data available at the time. Since then, additional post-marketing surveillance and longer-term registry data may have become available, though the fundamental safety question about very long-term use likely remains open.
The bigger picture
This review highlights a fundamental tension in growth factor therapy — the same biological properties that make a peptide therapeutic (stimulating tissue growth) can also raise cancer concerns. This pattern appears across multiple peptide classes, from growth hormone to IGF-1 to GLP-2. The GLP-2 cancer question is particularly relevant because teduglutide patients often need treatment for years or even life. As GLP-2 biology becomes better understood, the field needs long-term registry data to definitively answer whether this theoretical risk becomes a practical one.
Questions still open
- Does long-term teduglutide use beyond 30 months increase the risk of intestinal polyps or cancer in humans?
- Should patients on teduglutide undergo more frequent colonoscopy screening?
- Could modified GLP-2 analogs be designed that retain intestinal growth effects while reducing potential cancer-promoting properties?
Common questions
What is teduglutide used for?
Should patients on teduglutide be worried about cancer?
Read the original research
The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia.
The Journal of clinical endocrinology and metabolism, 103(8), 2827-2837
Citation
Orhan, Adile; Gögenur, Ismail; Kissow, Hannelouise. (2018). The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia.. The Journal of clinical endocrinology and metabolism, 103(8), 2827-2837. https://doi.org/10.1210/jc.2018-00655